$130.00
Metacos is intended to prevent the development of symptoms characteristic of bone damage, such as complications after surgery, pathological fractures, complications of radiation therapy, and compression of the spinal column. In addition, the drug is often used to treat hypercalcemia resulting from the development of a malignant tumor in patients at advanced stages of the pathological process.
Description
Metacos composition
active substance: zoledronic acid;
5 ml of concentrate contain anhydrous zoledronic acid 4 mg, in terms of zoledronic acid monohydrate – 4.264 mg;
excipients: mannitol (E 421), sodium citrate dihydrate, concentrated hydrochloric acid, sodium hydroxide, water for injection.
Dosage form
Concentrate for solution for infusion.
Pharmacological properties
Zolendronic acid has a specific effect on bone tissue. Its introduction allows you to stop bone resorption caused by osteoclasts. It has a selective effect on mineralized bone tissue, since it has a high degree of similarity with it. Despite the fact that zoledronic acid inhibits the resorption of cat tissue, it does not affect its mineralization, and also does not change its mechanical properties.
Indications
Metacos is intended to prevent the development of symptoms characteristic of bone damage, such as complications after surgery, pathological fractures, complications of radiation therapy, and compression of the spinal column. In addition, the drug is often used to treat hypercalcemia resulting from the development of a malignant tumor in patients at advanced stages of the pathological process.
Contraindications
Not prescribed for patients with previously identified hypersensitivity to zoledronic acid or other bisphosphonate-containing drugs. Metacos is not prescribed for nursing or pregnant women.
Children
It is unacceptable to use in the therapy of children, since there is no information about the features of using the drug in the therapy of this age group.
Application during pregnancy and lactation
At the moment, there is no reliable data on the effect of zoledronic acid on the development of the newborn and fetus, which does not allow the use of Metacos in the treatment of nursing and pregnant women.
Method of administration and dosage
Metacos should be administered by a specialist experienced in the treatment of bisphosphonate-containing drugs.
Before the introduction, 4 mg of the concentrate should be diluted in 100 ml of solvent. To dilute Metakos, it is permissible to use a 5% glucose solution or 0.9% sodium chloride. Patients receive the drug once every 3 or 4 weeks. The duration of treatment is determined by the doctor. To achieve the necessary therapeutic effect, the duration of treatment can vary from 2 to 3 months. The duration of the infusion is 15 minutes. The minimum time interval between infusions is 7 days.
The drug is not intended for joint administration with drugs containing calcium or other divalent cations. Also, the joint treatment of Metacos with other bisphosphonates is strictly prohibited.
Overdose
With the introduction of this drug in doses significantly higher than the established ones, the patient may develop an imbalance in the electrolyte balance of the plasma and renal dysfunction. If signs of hypocalcemia occur, the patient is prescribed intravenous calcium gluconate and symptomatic treatment.
Side effects
The administration of the drug can cause the development of headaches, paresthesias, dizziness, tremors of the extremities, thrombocytopenia, leukopenia, pancytopenia, anemia, increased drowsiness, epileptic seizures, sleep disturbances, impaired consciousness, conjunctivitis, uveitis, episcleritis, dyspeptic disorders, shortness of breath, cough reactions, bone pain, myalgia, arthralgia, osteonecrosis of the external auditory canal, renal dysfunction, arrhythmias, peripheral edema and muscle cramps.
Storage conditions and periods
Store in its original packaging in a place well protected from light at room temperature. The shelf life is 3 years.
Recent Reviews